Taoyuan, Taiwan, December 20, 2017 – Ulrich Faessler has been appointed CEO of SHL Medical.
Since the founding of SHL Group (hereinafter referred to as “SHL”) in the late 1980s, SHL’s founder Roger Samuelsson has been the CEO and Group President. For SHL to advance and adapt to the demands of the growing organization, a new global CEO role for SHL’s Medical division will be created.
The new global CEO for SHL Medical Holding will be Ulrich Faessler. Ulrich has been with SHL for over seven years and has been the Asian Managing Director for SHL Medical for the past five years. Ulrich will assume the global CEO role on January 1, 2018.
Roger Samuelsson, CEO of SHL Group, commented: "I am delighted that Ulrich has agreed to take on the responsibility of leading SHL Medical Holding. Ulrich knows SHL, our customers and the industry, and I’m convinced he’s the right person to lead the company in the future."
Roger will remain as President of SHL Group and will work closely with Ulrich.
SHL is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as auto injectors and pen injectors. With locations in Taiwan, Sweden, China and the U.S., it develops product enhancements and breakthrough drug delivery solutions for pharma and biotech clients globally.
Global Director Marketing SHL Group
T: +46 8 462 19 13